Generic drugmakers, which have saved Americans hundreds of billions of dollars in the past decade with their low-cost, copycat medicines, don't think they should join other health industries to finance a health care overhaul. Under the Senate Finance Committee bill approved Tuesday, the generic drug industry would pay $460 million over a decade through additional rebates to the state-federal Medicaid program for the poor. "That would be very harmful to our industry and our consumers," said Kathleen Jaeger, the president and CEO of the Generic Pharmaceutical Industry Association. She said the higher discounts would result in fewer companies making generics, which could push prices higher. Brand-name drugmakers, which would pay $80 billion as part of the proposed health overhaul and support the Finance Committee bill, scoff at their rivals' complaints. "Generics are getting off pretty light while everyone else gets whacked," said Joe Kelley, a lobbyist...
Comments